Experimental cancer drug NEV801 enters first human tests

NCT ID NCT02797795

Completed Disease control Sponsor: Neovia Oncology Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental drug called NEV801 in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The drug was given by IV in increasing doses to find the safest dose and to see if it had any anti-cancer effects. The study was completed, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NEV801 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not shrink tumors or may cause side effects. Only 78 people took part, so results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER SOLID TUMORS

Contacts and locations

Locations

Research Facility

Boston, Massachusetts, 02215, United States
Research Facility

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.